Online Inquiry
FGF Receptor 2 Antibody
SPA-03916
| Size | Price |
| 25 µg | Online Inquiry |
| 100 µg | Online Inquiry |
| More Options | Online Inquiry |
| Target Information | |
|---|---|
| Target Name | FGF Receptor |
| Gene Abbr. | FGFR2 |
| Gene ID | 2263 |
| Full Name | fibroblast growth factor receptor 2 |
| Alias | BBDS, BEK, BFR-1, CD332, CEK3 |
| Introduction | Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain. Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues. Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling. The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ.FGFR2 has several splicing isoforms, with ligand specificity largely determined by alternative splicing of exons 8 (IIIb) and 9 (IIIc). Alternative splicing is cell type specific, resulting in isoforms showing various tissue distribution and biological activities. Research studies have shown that mutations in the corresponding FGFR2 gene cause syndromes characterized by facial and limb defects, including LADD Syndrome, Crouzon Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, Pfeiffer Syndrome, Apert Syndrome, and Jackson-Weiss Syndrome. Investigators have also observed mutations and altered expression of FGFR2 in cases of gastric, endometrial, and breast cancer. |
| Product Details | |
|---|---|
| Host | Rabbit |
| Clonality | Monoclonal |
| Clone No. | D4L2V |
| Immunogen | Recombinant protein specific to the amino terminus of human FGFR2 protein. |
| Source/Purification | Antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human FGFR2 protein. |
| Usage | |
|---|---|
| Application | WB, IP, IF, IHC, FC |
| Dilutions | Western Blot (1:1000); Immunoprecipitation (1:50) |
| MW(KDa) | 92, 145 |
| Reactivity | Human, Mouse |
| Sensitivity | Endogenous |
| Specificity | It recognizes endogenous levels of total FGFR2 protein and does not cross-react with FGFR1 or FGFR4. |
| Storage & Handling | |
|---|---|
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol and less than 0.02% sodium azide. |
| Preservative | Less than 0.02% Sodium Azide |
| Storage Temp. | Store at -20 °C. |
| Handling | Do not aliquot the antibody. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.